Schlieren ZH/Fremont – Biognosys and Alamar Biosciences will be working and researching together in the future. Both companies will combine their respective expertise in proteomics to enable the earliest possible detection of diseases and pave the way for breakthroughs in plasma biology.
Biognosys from Schlieren and the Californian company Alamar Biosciences have announced a strategic collaboration. Together, the two companies aim to combine their specific expertise in biofluid-based proteomics for the benefit of biopharma and precision medicine research: Biognosys is one of the world's leading companies in mass spectrometry-based proteomics, while Alamar Biosciences is driving forward precision proteomics with its NULISA-Assays in order to detect diseases as early as possible.
This collaboration brings together Biognosys' expertise in unbiased discovery by data-independent acquisition in mass spectrometry (DIA-MS) and Alamar's pioneering immunoassays, the press release states. A joint study has provided the proof of concept. Both will present them at the annual meeting of the American Association for Cancer Research on April 9, 2024.
Building on this study, Biognosys and Alamar will continue to collaborate both commercially and scientifically: Biognosys will offer NULISA assays for previously difficult-to-measure cytokines, chemokines and other important disease-specific markers from plasma and biofluids at its state-of-the-art facility in Schlieren. In addition, both companies will continue to research plasma biology in order to decipher biological disease mechanisms.
"Our joint efforts will pave the way for a breakthrough in plasma biology," Biognosys founder and CEO Oliver Rinner is quoted as saying. "With this approach, we want to cover the entire dynamic range of plasma proteins."
Biognosys is a spin-off of the Swiss Federal Institute of Technology in Zurich(ETH) and is based in the Bio-Technopark Schlieren-Zurich. ce/mm